N,N-dimethyl-2-(1-methyl-1H-indol-3-yl)ethan-1-amine | 13366-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N,N-dimethyl-2-(1-methyl-1H-indol-3-yl)ethan-1-amine
• 英文别名: Indole, 3-(2-(dimethylamino)ethyl)-1-methyl-；N,N-dimethyl-2-(1-methylindol-3-yl)ethanamine
• CAS: 13366-47-7
• 化学式: C₁₃H₁₈N₂
• 分子量: 202.299
• InChiKey: WYFWKMQPMCPKLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  8.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-2-(1-methyl-1H-indol-3-yl)ethan-1-amine 、 富马酸 以 丙酮 为溶剂， 以0.108 g的产率得到N,N-dimethyl-2-(1-methyl-1H-indol-3-yl)ethan-1-amine fumarate
  参考文献：
  名称：

  [EN] N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS
  [FR] INDOLES N-SUBSTITUÉS ET AUTRES HÉTÉROCYCLES DESTINÉS AU TRAITEMENT DES TROUBLES DU CERVEAU

  摘要：

  公开号：

  WO2020176597A9
• 作为产物：
  描述：

  N-甲基-2-氟苯胺 在 正丁基锂 、 叔丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 正戊烷 为溶剂， 反应 9.3h， 生成 N,N-dimethyl-2-(1-methyl-1H-indol-3-yl)ethan-1-amine
  参考文献：
  名称：

  通过阴离子苯并环化合成功能化的吲哚和苯并稠合的杂环衍生物。

  摘要：

  报道了一种新的方法的发展，该方法用于区域选择性合成功能化的吲哚和六元苯并稠合的N，O和S杂环。关键步骤涉及生成苯并炔系链的乙烯基或芳基锂化合物，该化合物随后进行分子内阴离子环化。有机锂中间体与选择的亲电试剂的反应使得可以制备多种吲哚，四氢咔唑，二氢苯并吡啶，二苯并吡喃和二苯并噻喃并吡喃衍生物。最后，将该策略应用于合适的起始原料可以制备一些色胺和5-羟色胺类似物。

  DOI：

  10.1002/1521-3765(20020503)8:9<2034::aid-chem2034>3.0.co;2-i

文献信息

• HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
  申请人：Kozikowski Alan

  公开号：US20140128408A1

  公开（公告）日：2014-05-08

  Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.

  本发明公开了组蛋白去乙酰化酶抑制剂（HDACIs）及其组成物。公开了治疗疾病和状况的方法，其中抑制HDAC提供了益处，如癌症、神经退行性疾病、周围神经病变、神经疾病、创伤性脑损伤、中风、高血压、疟疾、自身免疫疾病、自闭症、自闭症谱系障碍和炎症。
• Synthesis and evaluation of N1-alkylindole-3-ylalkylammonium compounds as nicotinic acetylcholine receptor ligands
  作者：Edwin G. Pérez、Bruce K. Cassels、Christoph Eibl、Daniela Gündisch

  DOI：10.1016/j.bmc.2012.04.050

  日期：2012.6

  In this study thirty-three novel indole derivatives were designed and synthesized based on the structure of deformylflustrabromine B (1), a metabolite isolated from the marine bryozoan Flustra foliacea L. The syntheses were carried out using standard methodologies and in good yields. The molecules were tested for their affinities for the alpha 4 beta 2*, alpha 3 beta 4*, alpha 7* and (alpha 1)(2)beta 1 gamma delta nicotinic acetylcholine receptor (nAChR) sub-types. Binding assays showed that, among these ligands, compound 7c exhibited the highest affinity with K-i = 136.1, 93.9 and 862.4 nM for the alpha 4 beta 2*, alpha 3 beta 4*, and alpha 7* nAChRs subtypes, respectively. These results indicated that the indole core might be a useful scaffold for the development of new potent and selective nAChR ligands. (C) 2012 Elsevier Ltd. All rights reserved.
• Identification of Psychoplastogenic <i>N</i>,<i>N</i>-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure–Activity Relationship Studies
  作者：Lee E. Dunlap、Arya Azinfar、Calvin Ly、Lindsay P. Cameron、Jayashri Viswanathan、Robert J. Tombari、Douglas Myers-Turnbull、Jack C. Taylor、Ana Cristina Grodzki、Pamela J. Lein、David Kokel、David E. Olson

  DOI：10.1021/acs.jmedchem.9b01404

  日期：2020.2.13

  Ketamine, N,N-dimethyltryptamine (DMT), and other psychoplastogens possess enormous potential as neurotherapeutics due to their ability to potently promote neuronal growth. Here, we report the first-ever structure activity relationship study with the explicit goal of identifying novel psychoplastogens. We have discovered several key features of the psychoplastogenic pharmacophore and used this information to develop N,N-dimethylaminoisotryptamine (isoDMT) psychoplastogens that are easier to synthesize, have improved physicochemical properties, and possess reduced hallucinogenic potential as compared to their DMT counterparts.
• Hodson; Smith, Chemistry and industry, 1956, p. 740
  作者：Hodson、Smith

  DOI：——

  日期：——
• N-HYDROXYBENZAMIDE DERIVATIVES AS HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
  申请人：The Board of Trustees of the University of Illinois

  公开号：EP2670733B1

  公开（公告）日：2019-04-10